Latest evidence on COVID-19
This section is aimed at assisting public health professionals and is based on an ongoing rapid review of the latest evidence.
Diagnostic testing and screening
Diagnostic specimens, antibody testing, storage and shipping of specimens, testing methods and genetic characterisation of SARS-CoV-2, detection of variant viruses, neutralisation assays and antigenic characterisation of SARS-CoV-2 and biosafety.
Immune responses and immunity
Immune responses (cell-mediated immune response and antibody-mediated immune response and protective immunity) and population immunity
Incubation period, pathology and pathogenesis, viral shedding, and co-infections and secondary infections.
Risk factors and risk groups
Severity of COVID-19 is associated with increased age, male sex, and pre-existing medical conditions.
SARS-CoV-2 in children
Information about SARS-CoV-2 incidence in children, susceptibility and the severity of the disease for children and child vaccination.
Treatment and pharmaceutical prophylaxis
Several medicinal products have been studied or are currently undergoing clinical trials to assess their safety and efficacy as potential agents for pharmaceutical prophylaxis or treatment of COVID-19.